MaxCyte, Inc.

We are a leading commercial cell engineering company providing platform technologies for the discovery, development, and commercialization of next-generation cell therapeutics, including cell and gene therapies, and for innovative cell-based research and development. For over two decades, we have developed and commercialized our proprietary Flow Electroporation® technology. This technology is used by biopharmaceutical companies for the complex engineering of various cells. Electroporation is a method of transfection, which is the process of deliberately introducing molecules into cells by applying an electric field to temporarily increase the cell membrane's permeability. This controlled increase in permeability allows for the intracellular delivery of molecules, such as genetic material and proteins, that would not normally cross the cell membrane easily. Researchers leverage cell functions and machinery for research or therapeutic purposes. The ability to engineer living cells by introducing foreign molecules, such as gene editing systems and transgenes, has advanced biological research and led to numerous discoveries. Living human cells can also be engineered ex vivo, or outside the body, where they are repaired or reprogrammed to fight disease, with the engineered cell itself acting as the drug. Cell therapy is a rapidly growing treatment modality for human diseases. Recent developments in multiple U.S. Food and Drug Administration (FDA) approved cell therapies show promising data, suggesting they may provide long-lasting symptom amelioration or disease presence, which has driven significant investment and growth in cell-based therapies for therapeutic applications.